Treatment possibilities with Lysobact presented to over a thousand German doctors in Frankfurt

Organized by the German Enzyme Research Center (MEF), a professional meeting was held in Frankfurt where Bosnalijek representatives presented the possibilities of Lysobact ® and other products based on the action of lysozyme and vitamin B6, which are an integral part of the InnovaSpray ® IMMUN product.

The invitation to the meeting followed after Bosnalijek began exporting InnovaSpray ® IMMUN to Germany a month ago, which in a very short time generated great interest from the professional public, as evidenced by the participation of over a thousand doctors at the meeting from various parts of Germany.

The speakers were renowned experts in the field of enzyme therapy Dr. Rudolf Inderst, Dr. Hellmut Münch, and Dr. Uwe Peters, while Maja Pašić Kulenović, Director of the Development Department at Bosnalijek, spoke on behalf of Bosnalijek.

The General Director of Bosnalijek, Nedim Uzunović, emphasizes that the German professional public was presented with a wide range of applications for lysozyme-based products in strengthening the body's immune response to infections, treating diseases of the throat, oral and nasal cavities, and skin, as well as the benefits and treatment possibilities for other bacterial and viral infections with lysozyme-based products.

“Bosnalijek participated in the mentioned meeting as a company with 50 years of experience in therapy and production of lysozyme-based preparations and a contract manufacturer of InnovaSpray® IMMUN for the German market. These activities represent another step towards achieving the company's strategic goals, among which key ones are opening new markets and increasing the volume and value of exports. In the last five years, we have exported products worth over half a billion KM to three continents and more than twenty countries. The great interest of the professional public in Germany confirms the quality of our products, and at the same time will help in the strategic positioning of Bosnalijek in the German market, as well as in other European Union countries,” said Uzunović.

The professional public in Germany, among other things, was informed about numerous clinical studies conducted on lysozyme in Russia, Turkey, southeastern Europe including Bosnia and Herzegovina, Ukraine, and other countries, as well as awards that Bosnalijek's lysozyme-based products received in Russia as the first choice of therapy in treating oral cavity infections.